[go: up one dir, main page]

MX2009005798A - Recuperacion de apoplejia. - Google Patents

Recuperacion de apoplejia.

Info

Publication number
MX2009005798A
MX2009005798A MX2009005798A MX2009005798A MX2009005798A MX 2009005798 A MX2009005798 A MX 2009005798A MX 2009005798 A MX2009005798 A MX 2009005798A MX 2009005798 A MX2009005798 A MX 2009005798A MX 2009005798 A MX2009005798 A MX 2009005798A
Authority
MX
Mexico
Prior art keywords
certain
pharmaceutically acceptable
acceptable salt
additional therapeutic
stroke recovery
Prior art date
Application number
MX2009005798A
Other languages
English (en)
Inventor
Jack R Barber
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytrx Corp filed Critical Cytrx Corp
Publication of MX2009005798A publication Critical patent/MX2009005798A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona métodos para tratar apoplejía, que comprenden una cantidad efectiva de uno o más de ciertos derivados de hidroxilamina, a un sujeto con la necesidad de los mismos. La invención también proporciona composiciones farmacéuticas que comprenden cierto derivado de hidroxilamina o una sal farmacéuticamente aceptable del mismo, opcionalmente en combinación con uno o más agentes terapéuticos adicionales. En ciertas composiciones, el agente terapéutico adicional es un segundo derivado de hidroxilamina o una sal farmacéuticamente aceptable del mismo.
MX2009005798A 2006-12-01 2007-11-30 Recuperacion de apoplejia. MX2009005798A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87232906P 2006-12-01 2006-12-01
US92039607P 2007-03-27 2007-03-27
US99384807P 2007-09-14 2007-09-14
PCT/US2007/024711 WO2008070010A2 (en) 2006-12-01 2007-11-30 Hydroxylamine derivatives for the treatment of stroke

Publications (1)

Publication Number Publication Date
MX2009005798A true MX2009005798A (es) 2009-08-12

Family

ID=39322917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005798A MX2009005798A (es) 2006-12-01 2007-11-30 Recuperacion de apoplejia.

Country Status (9)

Country Link
US (1) US20090233917A1 (es)
EP (1) EP2089033A2 (es)
JP (1) JP2010511622A (es)
AU (1) AU2007328280A1 (es)
CA (1) CA2671049A1 (es)
IL (1) IL199030A0 (es)
MX (1) MX2009005798A (es)
TW (1) TW200838522A (es)
WO (1) WO2008070010A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004867C (en) * 2008-06-26 2020-09-15 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
WO2010058779A1 (ja) * 2008-11-18 2010-05-27 参天製薬株式会社 ピリジン－３－カルバルデヒド ｏ－（ピペリジン－１－イル－プロピル）－オキシム誘導体を有効成分として含有する網脈絡膜変性疾患の治療剤
WO2014071005A1 (en) * 2012-11-02 2014-05-08 Emory University Methods and compositions using neuroprotective steroids and thrombolytic agents
JP6678676B2 (ja) 2014-09-15 2020-04-08 オーファザイム エー／エス アリモクロモル製剤
US20160199393A1 (en) * 2015-01-08 2016-07-14 China Medical University Methods of treating brain ischemia or hypoxia
PT3448382T (pt) 2016-04-29 2020-11-20 Orphazyme As C/O Cobis As Arimoclomol para o tratamento de distúrbios associados à glucocerebrosidase
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
IL303026A (en) 2020-11-19 2023-07-01 Zevra Denmark As Processes for preparing arimoclomol citrate and intermediates thereof
AU2022354251A1 (en) * 2021-09-28 2024-04-04 Zevra Denmark A/S Dioxazines and their use in treatment of gba-related diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ285151A (en) * 1994-05-06 1998-09-24 Biorex Kutato Fejlesztoe Kft Hydroximic acid derivatives
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
WO2008039514A1 (en) * 2006-09-26 2008-04-03 Cytrx Corporation Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration

Also Published As

Publication number Publication date
WO2008070010A2 (en) 2008-06-12
CA2671049A1 (en) 2008-06-12
AU2007328280A1 (en) 2008-06-12
TW200838522A (en) 2008-10-01
EP2089033A2 (en) 2009-08-19
IL199030A0 (en) 2010-03-28
JP2010511622A (ja) 2010-04-15
WO2008070010A3 (en) 2008-07-24
US20090233917A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
MX2009005798A (es) Recuperacion de apoplejia.
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
PH12014500386A1 (en) Combination treatment for hepatitis c
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
MX2009011900A (es) Curacion de herida diabetica.
TNSN07419A1 (en) Methods for treating drug resistant cancer
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
ATE543492T1 (de) Behandlung von lungenkrebs
TNSN08506A1 (en) Substituted carboxamides
TW200639159A (en) Treatment of pain
TW200734334A (en) Treatment of substance abuse
EA201690327A1 (ru) Терапевтические способы
WO2008051527A3 (en) Sustained release of agents for localized pain management
WO2009019693A3 (en) Analgesic effect of jasmonate derivatives
NZ588470A (en) Pharmaceutical composition comprising a benzophenone derivative and an immunosuppressing agent for treating autoimmune diseases
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
WO2009137436A3 (en) Peptide conjugates
PL1817029T3 (pl) Pochodna izoksazolowa do łagodzenia bólu neuropatycznego

Legal Events

Date Code Title Description
FA Abandonment or withdrawal